Compare Freeport-McMoRan Inc (FCX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Mesoblast Limited — how do they compare? Freeport-McMoRan Inc trades at $69.14 (market cap $98.71B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Freeport-McMoRan Inc is far larger — about 45.7× Mesoblast Limited's market cap, and Freeport-McMoRan Inc pays a 0.85% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| FCX | MESO | |
|---|---|---|
Market Cap | $98.71B | $2.16B |
Sector | Basic Materials | Technology |
52-Week High | $71.73 | $20.96 |
52-Week Low | $35.34 | $12.88 |
Enterprise Value | $104.99B | $2.17B |
Dividend Yield | 0.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, up 2.1% today, with a bullish technical signal from moving averages but overbought RSI near 86. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.68 above the $0.60 forecast. Revenue reached $25.92B in 2025, with net income margin improving to 8.5%. Recent news highlights progress at the Grasberg mine and strong copper prices supporting operations.
Outlook is positive with a consensus price target of $73.85, implying 6% upside, backed by 61% analyst buy ratings. Risks include reliance on commodity cycles and potential volatility from economic shifts. The company's solid cash flow and debt reduction trend provide stability, but investors should monitor copper market dynamics for sustained growth.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
